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Introduction. ADT is used in the management of locally advanced and metastatic disease. The detrimental eﬀect of ADT on bone
density is well documented. This study assesses care gaps in screening, prevention and treatment of osteoporosis among prostate
cancer patients. Methods. We conducted a retrospective cohort study for patients diagnosed with non-metastatic prostate cancer
on ADT. Charts from a tertiary oncology center were assessed for utilization of DXA scan, prescription of calcium, vitamin D,
calcitonin and bisphosphonates.Bivariate analysis was used to determine the eﬀect of patient characteristics and likelihood for
osteoporosis screening. Results. 149 charts were reviewed, with 3-year mean follow-up. 58.8% of men received a baseline DXA,
of which 20.3% had a repeat DXA within their follow-up periods.In all, 28% were appropriately screened and managed for
osteoporosis (received repeat DXA, bisphosphonate). In bivariate analysis, the number of ADT injections which correlate with
the duration of androgen suppression was signiﬁcantly associated with the number of DXA scans. Conclusions. Our study found a
care gap in the screening, prevention, and treatment of osteoporosis in this population. Patients receiving the most ADT injections
were more likely to be screened. Our results suggest healthcare providers treating prostate cancer are insuﬃciently screening and
treatingthissusceptiblepopulation.WesuggestbaselinemeasurementofBMDattheinitiationofADTwithperiodicreassessment
during therapy.
1.Introduction
Prostate cancer is the most frequently diagnosed cancer and
is the most common cancer to aﬄict Canadian men; around
25,500 men will be diagnosed with prostate cancer in 2011
in Canada alone [1], and aside from nonmelanoma skin
cancer it is the most common cancer diagnosed in American
men [1]. Rates of prostate cancer in men are comparable2 Journal of Oncology
to rates of breast cancer in women and since 1995, the
incidence of prostate cancer in both the United States and
Canada have increased by 1 percent annually [1]. This is
largely due to the aging of the population [1]. Androgen
deprivation therapy (ADT) comprises of gonadotropin-
releasing hormone agonists and is usually administered in
a depot form. ADT remains the standard ﬁrst-line therapy
for metastatic prostate cancer. In addition to metastatic
disease, ADT has also been shown to improve survival in
patients with locally advanced or high-risk localized prostate
cancer [2–4]. There is an increasing role for ADT in patients
with localized prostate cancer and low-volume extracapsular
disease, [3, 5], and for patients with a biochemical PSA
recurrence [6].
In North American men with nonmetastatic prostate
cancer, the rate of use of ADT has increased from 3.7% in
1991 to 31% in 1999 [7]. Approximately 50% of men with
prostate cancer will receive ADT at some point after their
diagnosis [8]. The prevalence of prostate cancer has been
increasing,partlyduetotheincreaseduseofprostate-speciﬁc
antigen screening tests [9]. Therefore, the overall survival of
patients with prostate cancer is very high, with one report
estimating a 5-year survival of 98.1% [10]. Given the high
survival rate, this makes the long-term adverse eﬀects from
ADT even more important.
ADT has a number of important adverse eﬀects, most
of which are a consequence of drug-induced hypogonadism.
One of the most common and clinically signiﬁcant adverse
eﬀects includes osteoporosis and increased risk of fractures
[11].ThisisduetoADT’seﬀectonreducingcirculatinglevels
of estrogen and testosterone, which subsequently increases
rates of bone resorption and impairs new bone formation
[12,13].Severalstudieshaveshownthatthemaximaldecline
in BMD takes place in the ﬁrst year of ADT treatment, with
up to 10% decline in that ﬁrst year [12, 14–16]. This BMD
decline is evident even within months of starting ADT [12]
and subsequently leads to an increase in rate of fractures
[17, 18].
The objective of this study was to assess the management
practices of radiation oncologists who prescribe ADT for the
management of early prostate cancer and assess if a care gap
exists between current recommendations, as well as what is
seen in practice, also identify factors, which increased the
likelihood for radiation oncologists to screen men on ADT
for osteoporosis.
2. Methods
2.1. Population. Patients treated with Androgen depriva-
tion therapy followed at the Juravinski Cancer Centre in
Hamilton, Ontario, Canada, were assessed between years
2008 and 2009. This is a tertiary referral center with 2000
prostate cancer patients referred per year for all stages of
prostate cancer. All patients diagnosed with nonmetastatic
prostate cancer conﬁrmed by biopsy were screened, and
ADT treatment at any point during their prostate cancer
management was included in the study.
2.2. Study Design and Data Collection. Approval from the
Hamilton Health Sciences Center’s Ethics board was ob-
tained. All the patients treated at the Juravinski Cancer
Centre (JCC) were identiﬁed by hormonal treatment billing
number. There were a total of 745 patient charts, and every
ﬁfth chart was reviewed in its entirety from the patient’s
initial clinic visit to the date of the audit. The duration of
patient followup ranged from 6 months to 18 years, with the
majority of patients followed up for more than 3 years.
The data collected include patient age, date of prostate
cancer diagnosis, and age at which the diagnosis was made,
and clinical prostate cancer data including the Gleason score,
tumor stage, last PSA value, and the absence or presence
of bony metastases. The presence of known risk factors
for osteoporosis including prior fracture, corticosteroids
use or hyperthyroidism, diabetes, smoking, and alcohol use
phenytoin use, were also abstracted.
Furthermore, the presence or absence of osteoporosis
screening either before the initiation of ADT or during the
followup period was abstracted. This was characterized by
the performance of baseline Dual X-ray Absorptiometry
(DXA) scans if ADT was planned for more than 6 months
and repeat DXA scan at any point during the patient’s
followupforbothnormalandabnormalbaselineDXAscans.
The prescription of pharmacologic interventions was also
abstracted including, calcium and vitamin D supplementa-
tion, oral or intravenous bisphosphonates, and calcitonin
therapy [8].
Bivariate analysis was used to determine which of the
a b o v ef a c t o r sw a sm o r el i k e l yt op r o m p tp h y s i c i a n st os c r e e n
for osteoporosis. The factors assessed by bivariate analysis
included the number of ADT injections, patient age at
diagnosis, Gleason score, and PSA score at time of diagnosis.
3. Results
The charts of 149 men with nonmetastatic prostate cancer
were reviewed. Demographics are presented in Table 1.T h e
meanageofmenwas73.3years(SD =7.4).Themeanfollow-
up duration between diagnosis to time of data extraction
was 4.3 years (SD = 0.24), and these men received a mean
of 8.9 ADT (SD = 6.15) injections during their follow-
up period (Table 1). Risk factors for osteoporosis included
49.3% who had a history of smoking, of which 16.7% were
current smokers. In addition, 3.3% of men had a history of
corticosteroid use, and 2% had a history of hyperthyroidism.
Ah i s t o r yo fa l c o h o la b u s ew a sr e p o r t e di n1 3 . 3 %o fm e n ;
the history of abuse was clearly documented in the chart;
we could not verify the exact deﬁnition of abuse between
diﬀerent treating radiation oncologists. Five had a fracture
priortotreatmentwithADT;theseincludeonehipfractures.
A total of 58.8% (n = 87) of men on ADTs received a
baseline DXA scan, of which 20.3 (n = 17) had a repeat
DXA scan at any point within their individual follow-up
periods (Table 2). Bisphosphonates, calcium, vitamin D, and
calcitonin were prescribed to 12.7, 35.6, 36.9%, and 1.3%
of men respectively. Only 28% (42/148) of patients received
both a baseline BMD and a followup BMD at some pointJournal of Oncology 3
Table 1: Baseline characteristics of all patients, including collected prevalence of osteoporosis risk factors.
Age (n = 149) (Standard Deviation) 73.3 years (7.4)
Years between diagnosis and study entry (n = 117) 4.3 years (0.2)
Number of ADT injections received (n = 148) 8.9 (6.1)
PSA at ﬁrst visit (n = 150) 22.4 (61.5)
Gleason score (n = 149) 7.6 (1.0)
Height (n = 147) 170.7cm (21.2)
Weight (n = 150) 88.2kg (17.4)
Prostate cancer stage 1A, 1B, or 1C 24.6% (35/142)
Prostate cancer stage 2A, 2B, or 2C 44.4% (63/142)
Prostate cancer stage 3A, 3B, or 3C 31.0% (44/142)
Prior hip fracture before treatment 0% (0/147)
Prior vertebral fracture before treatment 1.4% (2/148)
Prior fracture before treatment (excluding hip or vertebral) 1.4% (2/148)
History of smoking 50.3% (74/147)
C u r r e n ts m o k e ra tﬁ r s tv i s i t 17% (25/147)
Steroid use during followup 3.3% (5/150)
SSRI use during followup 10.7% (16/150)
Anticonvulsant use during followup 4.7% (7/150)
HRT use during followup 13.5% (20/148)
Table 2: Evaluations screening strategies, prevention measures, and pharmacological treatment of osteoporosis.
Patient with BMD at baseline visit 58.8% (87/148)
Patient with BMD at any followup visit 20.3% (30/148)
Vitamin D supplementation during followup 36.9% (55/149)
Calcium supplementation during followup 35.6% (53/149)
Bisphosphonate use during followup 12.7% (18/142)
Calcitonin use during followup 0% (0/148)
Either a repeat BMD or treatment with a bisphosphonate during followup 28.4% (42/148)
during their followup or were started on a bisphosphonate
(Table 2).
Of the 87 patients who received an initial screening
BMD, 12 patients had a BMD in the osteoporosis range
≥2.5 and 13 patients in the osteopenia range (−2, 5< t-score
< −1) (Table 3). Of the 12 patients with an initial BMD
in the osteoporotic range, 3/12 (25%) patients were on a
bisphosphonate, and 6/12 (50%) were on calcium supple-
mentation, 6/12 (50%) were on vitamin D supplementation.
In addition, only 4/12 (25%) received a repeat BMD at
any time during the follow-up period. Of the 13 patients
with an initial BMD in the osteopenia range, 4/13 (25%)
patients were on a bisphosphonate, and 8/13 (50%) were
on calcium supplementation, 8/13 (50%) were on vitamin
D supplementation. Only 5/13 (25%) received a repeat BMD
at any time during the follow-up period.
Using bivariate analysis, we also assessed if there were
any prognostic factors which increased the likelihood for
screening for osteoporosis (Table 4). The number of ADT
injections increased the likelihood for being screened. The
mean number of ADT injections in patients who received
a follow-up DXA or were prescribed a bisphosphonate was
13.1 versus 7.9 (P ≤ 0.0001). Age, Gleason score, and PSA at
the initial visit were not associated with increased screening.
4. Discussion
Androgen-deprivation therapy (ADT) in men with prostate
cancer aﬀects bone metabolism and is associated with
a decrease in bone mineral density (BMD). The clinical
implications of this bone loss have been well recognized, and
managing skeletal health in this population is an emerging
challenge.
To prevent osteoporosis in men on ADT, clinicians have
been advised to screen patients for osteoporosis prior to
the initiation of ADT with DXA scan [19, 20]. In addition,
lifestyle modiﬁcations including smoking cessation, mod-
erating alcohol intake, and regular exercise are encouraged
[21, 22]. Pharmacological interventions, such as calcium,
vitamin D, are recommended for particular individuals
[19, 20, 23–25]. Bisphosphonates are also recommended for
particular individuals at high risk of fractures. Denosumab
is a newer agent, which has been approved recently by
the FDA [26]. It is a fully human monoclonal antibody4 Journal of Oncology
Table 3: Of the 87 patients with a baseline BMD, 12 patients had a BMD value in the osteoporosis range and 13 in the osteopenia range.
Percentage of patients on bisphosphonates, and calcium supplementation, vitamin D supplementation, calcitonin prescription was assessed
based on baseline BMD values.
Bisphosphonate
prescription
Calcium
supplementation
Vitamin D
supplementation
Calcitonin
prescription
Repeat BMD
at followup
Baseline BMD in osteoporosis range 25% (3/12) 50% (6/12) 50% (6/12) 0% (0/12) 25% (4/12)
Baseline BMD in osteopenia range 4/13 8/13 8/13 0% (0/13) 5/13
Table 4: Bivariate analysis was used to determine which of the above factors was more likely to prompt physicians to screen for osteoporosis.
Odds ratio 95% CI
Number of ADT treatments 1.24 1.096–1.403
Age 0.73 0.911–1.040
Gleason score 1.082 0.687–1.703
Years since diagnosis 1.109 0.915–1.345
Smoking history 1.43 0.565–3.621
Stage 1 A or B or C versus Stage 3 A or B or C 0.959 0.264–3.484
Stage 2 A or B or C versus Stage 3 A or B or C 1.61 0.539–4.808
against receptor activator of nuclear factor-kappa B ligand
which was also associated with increased bone mineral
density at all sites and a reduction in the incidence of
new vertebral fractures among men receiving androgen-
deprivation therapy for nonmetastatic prostate cancer [27].
Despite these recommendations, few clinicians order a
baseline DXA scan or prescribe bisphosphonates to patients
undergoing ADT [28]. Several retrospective studies have
assessed the actual management of bone health compared
to current recommendations for monitoring and treatment,
and these studies have shown that a care gap indeed exists in
this population [29–31].
As a result of the potential consequences of ADT,
expert guideline recommendations advocate for assessing
men prescribed ADT for osteoporosis and to estimate the
baseline fracture risk using an assessment tool, such as the
World Health Organization fracture risk assessment tool [6,
21, 32, 33]. It is also recommended that these patients should
receive a baseline DXA scan prior to initiating treatment
[6, 21]. In addition, calcium and vitamin D supplementation
are recommended to all men before starting ADT [34, 35].
Although bisphosphonates are not recommended for all
patients, they are for patients with documented osteoporosis
on DXA or a history of fractures [19, 36]. Bisphosphonates
have been shown in a number of studies to be eﬀective in
improvingbonemineraldensityinmenonADT[14,37,38].
Alternatives to bisphosphonates, including selective estrogen
receptor modulators and denosumab, have also been shown
to modestly increase in BMD of the hip and lumbar spine in
men on ADT [39, 40].
In this study, 149 patients from the Juravinski Cancer
Centre with nonmetastatic prostate cancer on ADT were
assessed. From the 149 patients, only 58.8% received a
baselineDXAscantoscreenforosteoporosispriortostarting
ADT. Only 20.3% of patients received a repeat DXA scan at
any point during their follow-up period.
Although it is recommended to all patients on ADT, only
35.6% and 36.9% were prescribed calcium and vitamin D
supplementation,respectively.Thereisnogeneralagreement
about whether or not men who are on a hormone blockade
(ADT) to treat prostate cancer should be taking calcium and
vitaminDsupplements;however,theredoesseemtobesome
consensus that they should.
Given that there are geographic and seasonal variations
in vitamin D, levels the issue becomes even more unclear.
However, men in North American and Western Europe
are at a higher risk for having low vitamin D levels so
calcium and vitamin D are especially important in men
receiving bisphosphonates or denosumab [41]. In terms of
antiresorptive treatments, 12.7% of patients were prescribed
a bisphosphonate and 1.3% prescribed calcitonin. We also
considered less stringent criteria for deﬁning screening and
management of osteoporosis in our population, where we
considered patient receiving a baseline DXA, follow-up DXA
at during their follow-up period, or were treated with an
anti-resorptive agent as being screened and managed appro-
priately. Although this is still not the optimal management
for this high-risk population, only 28% of patients met these
less stringent criteria we deﬁned. Adding to the evidence that
a care gap exists in this population, of the patients with an
initial BMD in the osteoporosis range, only 25% were on a
bisphosphonate, and only 50% were on calcium and vitamin
D supplementations, respectively. Furthermore, in all of the
charts we assessed, we found that none of the patients had
their fracture risk assessed using one of the available fracture
risk assessment tools (i.e., FRAX) [33, 42–44].
The results we report are quite alarming since this pop-
ulation of men are at particularly high risk for developing
osteoporosis and nonpathological fractures [17]. This group
of patients also received a relatively high number of ADT, a
mean of 8.9 treatments per patient, which further increases
their risk for future fractures [29]. In addition, the patientsJournal of Oncology 5
we assessed also have other risk factors for osteoporosis or
fractures, including a history of smoking glucocorticoid use,
and prescription of SSRIs or anticonvulsants.
At our institution, a deﬁnite care gap exists between the
recommended care for these patients, and what is seen in
clinicalpractice.Thelowratesofscreeningforandtreatment
of osteoporosis are similar to the rates reported by a group in
New Mexico, who assessed the rates of screening, prevention,
or treatment of osteoporosis in patients with nonmetastatic
prostate cancer on ADT [31]. In that study, only 13%
of patients received DXA scans, 21% of patients were on
treatment with an oral or IV bisphosphonates, and 16%
and 10% of patients were prescribed calcium and vitamin D
supplementation, respectively [31]. In another study which
includedpatientswithmetastaticprostatecancer,only14.7%
of patients received a DXA scan within the previous 3 years,
or treatment with bisphosphonates, calcitonin, or estrogen
within the past year, or supplementation with calcium and
vitamin D [29]. These other studies, in conjunction with our
ﬁndings, suggest that the lack of screening and treatment
of osteoporosis in these patients is not merely a problem
at the institutional level, but likely much more widespread.
This remains a signiﬁcant problem given the high incidence
of prostate cancer and the common use of ADT for its
management.
It is unclear why prostate cancer patients on ADT were
rarely screened for osteoporosis and recommended to start
calcium and vitamin D supplementation. These preventative
measures are recommended to all patients prior to starting
ADT.
It is also unclear why so few patients were prescribed an
antiresorptive agent for the treatment of osteoporosis. It is
likely a multifactorial issue leading to this care gap.
Using bivariate analysis, we determined that physicians
were more likely to screen for osteoporosis in patients with
a greater number of ADTs received. However, a decline
in BMD is evident even within months of starting ADT.
We hypothesize that a potential barrier to screening and
treatment of osteoporosis is due to a lack of education of
the oncologists and front-line staﬀ regarding the impact of
ADT on metabolic bone disease and its potential devastating
consequences. Another area where further education and
trainingmayberequiredistheeducationofcaregiversonthe
usefulness and application of a fracture risk assessment tool
to predict those at high risk of future fractures (i.e., FRAX).
This is quite evident as none of the patients we assessed had
a fracture risk assessment using any of the available tools.
Future research should emphasize the implementation
of the above-mentioned education initiatives for radiation
oncologists and nurses practitioners who treat prostate
cancer and assess if these education initiatives have any
impact on the screening practices in this group. Several
years ago, our group conducted a study assessing the use
of educational protocols to improve the knowledge of
family physicians in regards to evidence-based osteoporosis
management and fracture risk factors [45]. After 1 year, the
family physician’s awareness of their patient’s risk factors
increased, and the utilization of bone mineral density testing
in the high risk fracture group signiﬁcantly increased as well.
A similar system can be implemented for oncology practices.
Some limitations of our study included that the study
was retrospective, and only a single cancer center was
assessed. Also since this was a retrospective chart review,
comprehensive documentation was required, so that data
abstracted from the chart may not fully reﬂect the clinical
care that patients receive. Unless speciﬁcally documented,
we were not able to determine why patients were not
screened for osteoporosis, and if patients received council
regarding nonpharmacological recommendations to reduce
falls and fractures. In addition, since vitamin D and calcium
supplementation can be bought over the counter, these rates
may be an under estimation as the true rates may not be
captured through the chart review process. On the other
hand, adherence to calcium and vitamin D is in general poor
and conﬁrmation of adherence was not possible.
5. Conclusions
Our study found a suboptimal rate of osteoporosis screening
and preventative measures in men with nonmetastatic
prostate cancer on ADT. These results are concerning
given the high risk of this population to develop future
osteoporosis and nonfragility fractures. The barriers leading
to the care gap in this susceptible population remain to be
determined. We hypothesize a lack of education regarding
the actual degree of impact ADT has on bone metabolism,
and the availability of tools to identify individuals at high
risk of fractures are important factors that contribute to the
care gap. Future research should focus on determining the
speciﬁc barriers to screening and treatment of osteoporosis
andassessingdiﬀerentstrategiestocounteractthesebarriers.
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